Aripiprazole Tablet
Product Images NDC 68788-7808

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7808). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Prefferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis shows days from randomization up to 182 days, and the y-axis shows the proportion with relapse from 0 to 1. Below the x-axis, the number of subjects at risk over time for each group is displayed. Aripiprazole shows a lower relapse proportion compared to placebo throughout the study period.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A line graph showing the proportion of subjects with relapse over days from randomization up to 364 days, comparing Aripiprazole and placebo. The graph includes a legend indicating solid blue line for Aripiprazole and dashed red line for placebo, with the number of subjects at risk listed below the x-axis for both groups over time.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing the fold change and 90% confidence intervals for dehydro-aripiprazole levels (AUC and Cmax) when administered with various interacting drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and others (valproate, lithium, lorazepam). The horizontal axis measures change relative to a reference without interacting drugs.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic variables (DMVDR, AUC, Cmax, INR) of several drugs and enzymes interacting with a reference containing no interacting drug. Drugs include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine (including O-desmethylvenlafaxine), and escitalopram, with corresponding enzyme markers CYP2D6, CYP2C9, 2C19, and UGT1A4. The x-axis represents fold change relative to the reference, ranging from 0.5 to 3.0.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart titled 'Aripiprazole Fold Change and 90% CI' showing fold change and 90% confidence intervals in AUC and Cmax for Aripiprazole based on factors including CYP2D6 metabolizer status, gender, age, hepatic impairment, and severe renal impairment. The x-axis represents change relative to reference.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' illustrating changes in pharmacokinetic parameters AUC and Cmax relative to reference under various conditions: CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. Data points with error bars show fold change and confidence intervals along a horizontal axis ranging approximately from 0.5 to 3.0.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart illustrating the fold change and 90% confidence intervals in Aripiprazole exposure comparing different interacting drugs versus a reference without interacting drug. The chart lists various inhibitors, inducers, gastric acid blockers, and other drugs along the vertical axis against the change in AUC and Cmax on the horizontal axis.*

FDA Label Image

Aripiprazole Tablets 10mg (Aripiprazole Fig3 New)

Label for Aripiprazole Tablets 10 mg by Preferred Pharmaceuticals Inc. The label states the generic for Abilify and includes dosage information, storage instructions, and manufacturing details by Ascend Laboratories, LLC. The tablet is described as pink and imprinted with ARI 10. The label features directions in English and Spanish, a barcode, and a caution about federal law regarding drug transfer.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of Aripiprazole, showing its molecular framework with chlorinated phenyl, piperazine, and quinolinone groups as part of the active ingredient's chemical composition.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier plot showing the proportion of subjects with relapse over 182 days from randomization, comparing Aripiprazole and placebo groups. The graph includes a table below indicating the number of subjects at risk at various time points for both Aripiprazole and placebo groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.